GlassScriptPhysician profile
Syed T Ali
NPI 1396733713
$2,150.00
in general payments reported to CMS, 2019-2025
26 companies · $56.48 in 2025
The $56.48 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $46.08 · 2021: $410 · 2022: $56.25 · 2023: $207 · 2024: $114 · 2025: $56.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $294.49 | 2019 | |
| Ucb, INC. | $281.53 | 2019-2021 | |
| Biogen, INC. | $253.51 | 2019-2024 | Spinraza, Qalsody |
| Genentech USA, INC. | $192.35 | 2019 | |
| Amgen INC. | $165.72 | 2019-2020 | |
| Eisai INC. | $122.10 | 2023 | |
| Abbvie INC. | $111.74 | 2021 | |
| Lilly USA, LLC | $97.19 | 2021-2025 | Emgality |
| Novartis Pharmaceuticals Corporation | $94.29 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $70.04 | 2019 | |
| Sk Life Science, INC. | $63.70 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $60.32 | 2023-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $50.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.48 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $38.90 | 2023 | Trudhesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34.75 | 2025 | Watchman Flx |
| Argenx US, INC. | $24.56 | 2024 | Vyvgart Hytrulo |
| Allergan, INC. | $24.32 | 2019 | |
| Adamas Pharmaceuticals, INC. | $20.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.11 | 2019 | |
| Neurocrine Biosciences, INC. | $17.68 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.56 | 2019 | |
| Tanabe Pharma America, INC. | $16.22 | 2019 | |
| Acorda Therapeutics, INC | $14.83 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.83 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.